Transforming the Care of Patients With Non-Small-Cell Lung Cancer: Optimizing Immune Checkpoint Inhibitor Therapy

CE / CME

Transforming the Care of Patients With Non-Small-Cell Lung Cancer: Optimizing Immune Checkpoint Inhibitor Therapy
Registered Nurses: 1.50 Nursing contact hours, includes 1.50 hour of pharmacology credit

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Released: August 17, 2022

Expiration: August 16, 2023

Elizabeth Krueger
Elizabeth Krueger, NP

Pretest

Progress
1 2
Course Completed
1.
Which level of PD-L1 expression is recommended by experts to consider frontline single-agent immune checkpoint inhibitor (ICI) therapy with atezolizumab, cemiplimab-rwlc, or pembrolizumab in metastatic non-small-cell lung cancer (NSCLC) with no actionable biomarkers?
2.
Which treatment is recommended as initial therapy for metastatic adenocarcinoma NSCLC in a patient with PD-L1 tumor expression ≤1% and KRAS G12C mutation?
3.
A 75-year-old female with advanced NSCLC has been receiving an ICI regimen. At her follow-up appointment she has no complaints. A resulting thyroid stimulating hormone (TSH) concentration is 12 mIU/L (baseline TSH = 1 mIU/L), and free T4 is within normal limits. How should her immunotherapy-related adverse event be managed?